Linked from

The 12 pages that link to Celecoxib, each with the reason it gives.

• Nonsteroidal anti-inflammatory drugBroader topic: Its selectivity can reduce some stomach risks while leaving cardiovascular concerns.

• CyclooxygenaseRelated: It illustrates pharmacological selectivity between the two major cyclooxygenase isoforms.

• ProstaglandinCompared with: Its COX-2 selectivity contrasts with drugs that inhibit both major cyclooxygenase forms.

• Arachidonic acidBroader topic: It selectively blocks one major enzymatic route from arachidonic acid.

• EicosanoidRelated: It exemplifies attempts to suppress inflammatory prostaglandins while sparing cyclooxygenase-1.

• IbuprofenCompared with: Its greater COX-2 selectivity distinguishes it from ibuprofen’s inhibition of both COX-1 and COX-2.

• DiclofenacCompared with: Its greater COX-2 selectivity contrasts with diclofenac’s inhibition of both major cyclooxygenase forms.

• NaproxenCompared with: Its greater COX-2 selectivity distinguishes it from naproxen’s inhibition of both major cyclooxygenase forms.

• MeloxicamCompared with: Both favor COX-2 inhibition, but celecoxib is more selective.

• PyrazoleBroader topic: Its central pyrazole ring is part of the structure that supports selective drug activity.

• IndometacinCompared with: Its greater COX-2 selectivity distinguishes its gastrointestinal and cardiovascular risk profile from indometacin’s.

• PiroxicamCompared with: Its greater COX-2 selectivity offers a different gastrointestinal-risk profile from piroxicam, with cardiovascular trade-offs.